Clinical Trials

64 enrolled 14 charts

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02142803 2025-11-13

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

50 enrolled 16 charts

CNSGynecologic

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT03740165 2025-10-22

KEYLYNK-001

Phase 3 Active not recruiting

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03188432 2025-10-21

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

50 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03776812 2025-10-07

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

178 enrolled 21 charts

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01012817 2025-09-15

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

88 enrolled 23 charts

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02498600 2025-08-29

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

100 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

453 enrolled 18 charts 1 FDA

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04209855 2025-08-27

MIRASOL

Phase 3 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT05708924 2025-08-14

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1 Terminated

1 enrolled 5 charts

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

6 enrolled 11 charts

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03522246 2025-06-24

ATHENA

1,097 enrolled 26 charts

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT03783949 2025-06-11

EUDARIO

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04019288 2025-06-11

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

12 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02520154 2025-06-08

Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled 12 charts

Fallopian Tube Neoplasms

NCT02713386 2025-05-25

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Completed

147 enrolled 18 charts

Fallopian Tube Neoplasms

NCT04442126 2025-05-23

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

52 enrolled 33 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02569957 2025-05-04

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Terminated

1 enrolled 5 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03054298 2025-04-29

CAR T Cells in Mesothelin Expressing Cancers

GynecologicOther solid neoplasmThoracic

65 enrolled 14 charts

Adenocarcinoma of Lung, Mesothelioma, Malignant, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04406623 2025-01-30

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

27 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

40 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05261490 2024-11-19

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

10 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635489 2024-10-03

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Completed

100 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02903771 2024-09-19

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

32 enrolled 37 charts

106 enrolled 14 charts 1 FDA

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04296890 2024-08-07

SORAYA

Phase 3 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03759600 2024-07-16

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

20 enrolled 42 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02606305 2024-06-14

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1/2 Completed

264 enrolled 41 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03621982 2024-06-13

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Phase 1 Terminated

78 enrolled 39 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03759587 2024-06-07

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

19 enrolled 39 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03093155 2024-05-14

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

78 enrolled 18 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03311334 2024-04-18

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

47 enrolled 11 charts

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Kidney Neoplasms, Wilms Tumor, Ovarian Neoplasms

NCT01962948 2024-03-26

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

12 enrolled 8 charts